was read the article
array:23 [ "pii" => "S2013251423001190" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2021.07.013" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "944" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Nefrologia (English Version). 2023;43:380-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0211699521001740" "issn" => "02116995" "doi" => "10.1016/j.nefro.2021.07.012" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "944" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Nefrologia. 2023;43:380-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Director</span>" "titulo" => "Respuesta inmunológica humoral insuficiente a la 2.<span class="elsevierStyleSup">a</span> dosis de vacuna anti-COVID19 mRNA-1273 (Moderna) en pacientes portadores de trasplante renal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "380" "paginaFinal" => "382" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Suboptimal humoral immunological response to the 2nd dose of anti-COVID19 mRNA-1273 vaccine (Moderna) in kidney transplant patients" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1346 "Ancho" => 2380 "Tamanyo" => 100880 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Porcentaje de pacientes y controles que desarrollaron Ac anti-Spike SARS-CoV 2, a un título superior a 50<span class="elsevierStyleHsp" style=""></span>UA/ml, las 8 semanas de la administración de la 2.<span class="elsevierStyleSup">a</span> dosis de vacuna mRNA-1273 (Moderna).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús Martín-García, Gilda Carreño Cornejo, Rosario Manzanedo Bueno, Consolación Rosado Rubio, David Menéndez González, Dolores Barreda Grande, Carmen Felipe Fernández" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "Martín-García" ] 1 => array:2 [ "nombre" => "Gilda" "apellidos" => "Carreño Cornejo" ] 2 => array:2 [ "nombre" => "Rosario" "apellidos" => "Manzanedo Bueno" ] 3 => array:2 [ "nombre" => "Consolación" "apellidos" => "Rosado Rubio" ] 4 => array:2 [ "nombre" => "David" "apellidos" => "Menéndez González" ] 5 => array:2 [ "nombre" => "Dolores" "apellidos" => "Barreda Grande" ] 6 => array:2 [ "nombre" => "Carmen" "apellidos" => "Felipe Fernández" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2013251423001190" "doi" => "10.1016/j.nefroe.2021.07.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251423001190?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699521001740?idApp=UINPBA000064" "url" => "/02116995/0000004300000003/v2_202410220454/S0211699521001740/v2_202410220454/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2013251423001050" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2021.07.011" "estado" => "S300" "fechaPublicacion" => "2023-05-01" "aid" => "930" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "cita" => "Nefrologia (English Version). 2023;43:378-80" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "UMOD-related autosomal dominant tubulointerstitial kidney disease: an unfavourable novel mutation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "378" "paginaFinal" => "380" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nefropatía tubulointersticial autosómica dominante por mutación en UMOD: nueva variante con comportamiento agresivo" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 563 "Ancho" => 750 "Tamanyo" => 104120 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Masson's trichrome staining ×100: interstitium with abundant fibrosis, tubular atrophy, acute tubular damage with regeneration and chronic inflammatory infiltrate.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro Viaño Nogueira, Carmen de Lucas Collantes, Valentina Ortiz Cabrera, Andrés Urquía Renke, Cristina Aparicio López" "autores" => array:5 [ 0 => array:3 [ "preGrado" => "MD" "nombre" => "Pedro" "apellidos" => "Viaño Nogueira" ] 1 => array:3 [ "preGrado" => "MD, PhD" "nombre" => "Carmen" "apellidos" => "de Lucas Collantes" ] 2 => array:3 [ "preGrado" => "MD, PhD" "nombre" => "Valentina" "apellidos" => "Ortiz Cabrera" ] 3 => array:3 [ "preGrado" => "MD" "nombre" => "Andrés" "apellidos" => "Urquía Renke" ] 4 => array:3 [ "preGrado" => "MD, PhD" "nombre" => "Cristina" "apellidos" => "Aparicio López" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0211699521001557" "doi" => "10.1016/j.nefro.2021.07.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699521001557?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251423001050?idApp=UINPBA000064" "url" => "/20132514/0000004300000003/v1_202309041339/S2013251423001050/v1_202309041339/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Suboptimal humoral immunological response to the 2nd dose of anti-COVID19 mRNA-1273 vaccine (Moderna) in kidney transplant patients" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "380" "paginaFinal" => "382" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jesús Martín-García, Gilda Carreño Cornejo, Rosario Manzanedo Bueno, Consolación Rosado Rubio, David Menéndez González, Dolores Barreda Grande, Carmen Felipe Fernández" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Jesús" "apellidos" => "Martín-García" "email" => array:1 [ 0 => "jmarting@senefro.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Gilda" "apellidos" => "Carreño Cornejo" ] 2 => array:2 [ "nombre" => "Rosario" "apellidos" => "Manzanedo Bueno" ] 3 => array:2 [ "nombre" => "Consolación" "apellidos" => "Rosado Rubio" ] 4 => array:2 [ "nombre" => "David" "apellidos" => "Menéndez González" ] 5 => array:2 [ "nombre" => "Dolores" "apellidos" => "Barreda Grande" ] 6 => array:2 [ "nombre" => "Carmen" "apellidos" => "Felipe Fernández" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Sección de Nefrología, Complejo asistencial de Ávila, Ávila, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta inmunológica humoral insuficiente a la 2.<span class="elsevierStyleSup">a</span> dosis de vacuna anti-COVID19 mRNA-1273 (Moderna) en pacientes portadores de trasplante renal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1880 "Ancho" => 2497 "Tamanyo" => 156263 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Titres of anti-Spike SARS-CoV-2 antibodies of patients and controls 8 weeks after the 2nd dose of mRNA-1273 (Moderna) vaccine. Mean and 95% CI.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Since the start of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), various groups of researchers have found a weak immune response in patients with solid organ transplants.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> This finding and the fact that some transplant patients have suffered from COVID-19 after being fully vaccinated with two doses, has led to the recommendation, in some countries, of a third dose of vaccine in these patients.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We prospectively studied the humoural response to the mRNA-1273 (Moderna) vaccine in 73 kidney transplant recipients by quantitatively determining anti-Spike IgG antibodies to SARS-CoV-2, immediately before the second dose and eight weeks after vaccine administration, analysed by microparticle chemiluminescence (Abbott Alinity system [ref. value + >50 AU/ml]). The results were compared with the response to the same mRNA-1273 vaccine administered to 30 patients on haemodialysis (HD), 12 on peritoneal dialysis (PD), 21 pre-dialysis (pre-D) and 47 controls, who were healthy hospital workers.</p><p id="par0015" class="elsevierStylePara elsevierViewall">As this was a prospective study, it was approved by the Independent Ethics Committee for Clinical Trials with medicines (IECm) of the institution, Gerencia de Asistencia Sanitaria de Ávila [Ávila Healthcare Management].</p><p id="par0020" class="elsevierStylePara elsevierViewall">The mean age of the transplant recipients was 60.12 ± 10.4 and the time since transplantation was 123–11,888 days; 56.1% were male. Four patients who had previous SARS-CoV-2 infection and three patients who had been in close contact and had a high suspicion of infection had very high titres (40,374.6 ± 55,211.5 AU/ml) and were excluded from the analysis. The response to the first dose of the vaccine, defined by IgG levels >50 AU/ml, was only found in 16.4% (11 patients) with a mean anti-Spike IgG antibody (Ab) titre of 270.8 ± 322.0 (median: 172.9; r = 52.6–19,650.3); 79.8% had levels below 50 AU/ml, and 21 (28.7%) were anergic (0–<1 AU/ml). Eight patients on HD, one on PD and two pre-D had already had clinical SARS-CoV-2 infection and all developed a strong anti-Spike Ab response to the first dose of vaccine (patients on HD: 42,181 ± 22,798; PD: 35,418.4 AU/ml; pre-D: 36,934.3 ± 35,026.7). Of the rest, 90.9% of patients on HD, 72.7% of those on PD and 78.9% of the pre-D developed an Ab response >50 AU/ml, with mean figures of 377.5 ± 350.4 AU/ml (median: 314.9) in HD; 1176.5 ± 1823.8 (median: 646.7) in PD and 1158.3 ± 1431.1 (median: 683.6) in pre-D, with significant differences compared to the transplant recipients (p = 0.004). The transplant recipients with IgG anti-Spike <50 AU/ml were older, 63.7 ± 9 vs 58.5 ± 10 (p = 0.1), with more lymphopenia 1568 ± 731 vs 2060 ± 680 (p = 0.05); and there was a correlation between IgG anti-Spike and lymphocytes: R = 0.32 (p = 0.007); a certain negative correlation was also detected with tacrolimus, R = −0.24, and prednisone, R = −0.14, although not statistically significant (p = 0.1). Eight weeks after the second dose of mRNA-1273, another antibody determination was performed; 35 transplant recipients already had levels >50 AU/ml, (53.03% vs 100% of patients on HD, PD, pre-D and healthy controls) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The anti-Spike Ab titre was also lower than the rest of the groups: mean 1544.11 ± 4279.58 AU/ml (95% CI: 2576.58–511.6) vs 4000.3 ± 5567.2 (95% CI: 6683.62–1317.03) on HD; 3709.3 ± 2889.6 (95% CI: 5650.61–1768.03) on PD; 7288.4 ± 7849.1 (95% CI: 12,031.6–2545.2) in pre-D; and significantly lower than those of healthy controls: mean 16,226.3 ± 11,319.8 (95% CI: 19,462.5–2545.2) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). There was no evidence of any serious events after the first or second doses, or any rejection phenomenon or variation in serum creatinine. In the follow-up period, none of the patients or controls developed COVID-19 infection, despite having a low antibody titre, perhaps related to a certain degree of cellular immunity.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">This study shows that, in transplant recipients, the immunisation achieved with the second dose of mRNA-1273 (Moderna) vaccine improves considerably, but without reaching a prevalence of at least 70% in this population, with anti-Spike anti-IgG Ab titres significantly lower than the controls and the rest of the groups of patients with advanced chronic kidney disease (ACKD). As a large proportion of transplant recipients remain at risk of COVID-19, another third dose of vaccine should be provided as soon as possible, as is already being done in other countries.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1338 "Ancho" => 2380 "Tamanyo" => 129987 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Percentage of patients and controls who had developed anti-Spike SARS-CoV-2 Ab, at a titre above 50 AU/ml, at eight weeks after administration of the second dose of mRNA-1273 (Moderna) vaccine.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1880 "Ancho" => 2497 "Tamanyo" => 156263 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Titres of anti-Spike SARS-CoV-2 antibodies of patients and controls 8 weeks after the 2nd dose of mRNA-1273 (Moderna) vaccine. Mean and 95% CI.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.J. Boyarsky" 1 => "W.A. Werbel" 2 => "R.K. Avery" 3 => "A.A.R. Tobian" 4 => "A. Massie" 5 => "D.L. Segey" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JAMA" "fecha" => "2021" "volumen" => "325" "paginaInicial" => "2204" "paginaFinal" => "2206" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Marion" 1 => "A. del Bello" 2 => "F. Abravanel" 3 => "C. Couat" 4 => "S. Faguer" 5 => "L. Esposito" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/M21-1341" "Revista" => array:4 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2021" "paginaInicial" => "M21" "paginaFinal" => "1341" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.M. Wadei" 1 => "T.A. Gonwa" 2 => "J.C. Leoni" 3 => "S.Z. Shah" 4 => "N. Aslam" 5 => "L.L. Speicher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajt.16618" "Revista" => array:4 [ "tituloSerie" => "Am J Transplant" "fecha" => "2021" "volumen" => "23" "itemHostRev" => array:3 [ "pii" => "S1081120620301757" "estado" => "S300" "issn" => "10811206" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "host" => array:2 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "DGS-Urgent. Vaccins contre la Covid-19: modalities d’administration des rappels" "fecha" => "2021" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://www.mesvaccins.net/textes/gs_urgent_n43_vaccination_modalites_d_administration_des_rappels.pdf" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection of pre-existing SARS-Cov-2-reactive T cells in unexposed renal transplant patient" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Anft" 1 => "A. Blazquez-Navarro" 2 => "U. Stervbo" 3 => "S. Skrzypczyk" 4 => "O. Witzke" 5 => "R. Wirth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40620-021-01092-0" "Revista" => array:6 [ "tituloSerie" => "J Nephrol" "fecha" => "2021" "volumen" => "34" "paginaInicial" => "1025" "paginaFinal" => "1037" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34228322" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Kamar" 1 => "F. Abravanel" 2 => "O. Marion" 3 => "J. Izopet" 4 => "A. del Bello" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc2108861" "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2021" "volumen" => "38" "paginaInicial" => "661" "paginaFinal" => "662" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000004300000003/v1_202309041339/S2013251423001190/v1_202309041339/en/main.assets" "Apartado" => array:4 [ "identificador" => "35436" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000004300000003/v1_202309041339/S2013251423001190/v1_202309041339/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251423001190?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 8 | 8 | 16 |
2024 October | 42 | 52 | 94 |
2024 September | 56 | 28 | 84 |
2024 August | 57 | 70 | 127 |
2024 July | 35 | 20 | 55 |
2024 June | 45 | 42 | 87 |
2024 May | 51 | 41 | 92 |
2024 April | 46 | 40 | 86 |
2024 March | 33 | 20 | 53 |
2024 February | 33 | 32 | 65 |
2024 January | 23 | 23 | 46 |
2023 December | 28 | 26 | 54 |
2023 November | 43 | 41 | 84 |
2023 October | 104 | 235 | 339 |
2023 September | 102 | 101 | 203 |
2023 August | 19 | 21 | 40 |